Taneza, Mishel A.
HRN: 11-39-46 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/22/2025
CEFTRIAXONE 1G (VIAL)
04/22/2025
04/29/2025
IV
2gms
OD
Acute Uncomplicated Pyelonephritis
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes